메뉴 건너뛰기




Volumn 27, Issue 6, 2014, Pages 1154-1158

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma

Author keywords

NRAS; AZD6244; ERK; Melanoma; Trametinib

Indexed keywords

CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; SELUMETINIB; TRAMETINIB; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

EID: 84911416288     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12303     Document Type: Article
Times cited : (47)

References (14)
  • 1
    • 70350066163 scopus 로고    scopus 로고
    • Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control
    • Aronov, A.M., Tang, Q., Martinez-Botella, G. et al. (2009). Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362-6368.
    • (2009) J. Med. Chem. , vol.52 , pp. 6362-6368
    • Aronov, A.M.1    Tang, Q.2    Martinez-Botella, G.3
  • 2
    • 84875235432 scopus 로고    scopus 로고
    • MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    • Ascierto, P.A., Schadendorf, D., Berking, C. et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
    • (2013) Lancet Oncol. , vol.14 , pp. 249-256
    • Ascierto, P.A.1    Schadendorf, D.2    Berking, C.3
  • 3
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
    • (2011) N. Engl. J. Med. , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 4
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
    • (2012) N. Engl. J. Med. , vol.367 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3
  • 5
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 6
    • 84880064248 scopus 로고    scopus 로고
    • Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity
    • Ishii, N., Harada, N., Joseph, E.W. et al. (2013). Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050-4060.
    • (2013) Cancer Res. , vol.73 , pp. 4050-4060
    • Ishii, N.1    Harada, N.2    Joseph, E.W.3
  • 7
    • 84870289371 scopus 로고    scopus 로고
    • Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
    • Kwong, L.N., Costello, J.C., Liu, H. et al. (2012). Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med., 18, 1503-1510.
    • (2012) Nat. Med. , vol.18 , pp. 1503-1510
    • Kwong, L.N.1    Costello, J.C.2    Liu, H.3
  • 8
    • 84869067183 scopus 로고    scopus 로고
    • Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
    • Lito, P., Pratilas, C.A., Joseph, E.W. et al. (2012). Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682.
    • (2012) Cancer Cell , vol.22 , pp. 668-682
    • Lito, P.1    Pratilas, C.A.2    Joseph, E.W.3
  • 9
    • 84900442808 scopus 로고    scopus 로고
    • Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
    • Lito, P., Saborowski, A., Yue, J. et al. (2014). Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 25, 697-710.
    • (2014) Cancer Cell , vol.25 , pp. 697-710
    • Lito, P.1    Saborowski, A.2    Yue, J.3
  • 10
    • 84896757312 scopus 로고    scopus 로고
    • Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma
    • Ma, X.H., Piao, S.F., Dey, S. et al. (2014). Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Investig. 124, 1406-1417.
    • (2014) J. Clin. Investig. , vol.124 , pp. 1406-1417
    • Ma, X.H.1    Piao, S.F.2    Dey, S.3
  • 12
    • 84874613332 scopus 로고    scopus 로고
    • Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
    • Posch, C., Moslehi, H., Feeney, L. et al. (2013). Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl Acad. Sci. USA 110, 4015-4020.
    • (2013) Proc. Natl Acad. Sci. USA , vol.110 , pp. 4015-4020
    • Posch, C.1    Moslehi, H.2    Feeney, L.3
  • 13
    • 84904087853 scopus 로고    scopus 로고
    • Evaluating melanoma drug response and therapeutic escape with quantitative proteomics
    • Rebecca, V.W., Wood, E.R., Fedorenko, I.V. et al. (2014). Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol. Cell. Proteomics, 13, 1844-1854.
    • (2014) Mol. Cell. Proteomics , vol.13 , pp. 1844-1854
    • Rebecca, V.W.1    Wood, E.R.2    Fedorenko, I.V.3
  • 14
    • 84891898344 scopus 로고    scopus 로고
    • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
    • Shi, H., Hugo, W., Kong, X. et al. (2014). Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4, 80-93.
    • (2014) Cancer Discov , vol.4 , pp. 80-93
    • Shi, H.1    Hugo, W.2    Kong, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.